Open AccessBudget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
Author(s) -
Anshul Shah,
Jonathan Tosh,
Apoorva Ambavane,
Andreas Nikolaou,
Cosmina Hogea,
Yevgeniy Samyshkin,
Boris Gorsh,
Eric M. Maiese,
Feng Wang
Publication year - 2021
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s310619
Subject(s) - medicine , emergency medicine , intensive care medicine
Estimate the budget impact of belantamab mafodotin (belamaf) for patients with relapsed/refractory multiple myeloma (RRMM) who have received ≥4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.